NCT06365905 Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding
| NCT ID | NCT06365905 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Endometrial Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-03-27 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2024-03-27 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates if AI can be used with transvaginal ultrasound images for early detection of endometrial cancer or premalignant lesions.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 55 years * At least one episode of postmenopausal bleeding (PMB) * Endometrial biopsy available from at Mayo Clinic (MN, AZ, FL), Mayo Clinic Health System (MCHS), or an external institution * Acceptance to participate in the study Exclusion Criteria: * Diagnostic tests performed more than 90 days apart * Physical impediment/refusal to undergo transvaginal ultrasound (TVUS)
Contact & Investigator
Gretchen E Glaser, MD
PRINCIPAL INVESTIGATOR
Mayo Clinic in Rochester
Frequently Asked Questions
Who can join the NCT06365905 clinical trial?
This trial is open to female participants only, aged 55 Years or older, studying Endometrial Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06365905 currently recruiting?
Yes, NCT06365905 is actively recruiting participants. Contact the research team at mayocliniccancerstudies@mayo.edu for enrollment information.
Where is the NCT06365905 trial being conducted?
This trial is being conducted at Scottsdale, United States, Jacksonville, United States, Rochester, United States.
Who is sponsoring the NCT06365905 clinical trial?
NCT06365905 is sponsored by Mayo Clinic. The principal investigator is Gretchen E Glaser, MD at Mayo Clinic in Rochester. The trial plans to enroll 300 participants.